Wegovy guide

Wegovy for Weight Loss: Clinical Evidence

Wegovy weight-loss outcomes are well-documented in FDA pivotal trials. This page summarizes mean body-weight change versus placebo, timing to peak effect, BMI eligibility criteria, and how individual results vary. Editorial review based on published prescribing information.

8 min read

SSL secured
HTTPS-only, TLS 1.3
FTC §255 compliant
Inline affiliate disclosures
Editorially independent
Reviewers paid flat fee
WCAG 2.2 AA target
Accessibility statement

More Wegovy guides

Wegovy weight-loss results

Wegovy produced 14.9% mean body-weight reduction in the STEP-1 pivotal trial at 68 weeks — substantially more than placebo and competitive with other approved weight-loss medications. This page details the clinical evidence, eligibility criteria, and what individual results look like in practice.

How effective is Wegovy?

Mean body-weight change at 68 weeks in the STEP-1 trial. Source: FDA prescribing information.

Wegovy−14.9%

14.9%

Placebo−2.4%

GLP-1 class ceiling (tirzepatide / SURMOUNT-1)−22.5%

22.5%

Vs placebo

+12.5 pts

Strong active-treatment signal

Wegovy for Weight Loss: Clinical Evidence

Wegovy weight-loss results

How effective is Wegovy?

Expected weight-loss curve

Eligibility criteria

Who Wegovy is for — and not for

Often a fit for

Not appropriate if

What individual results actually look like

Timing — when results show up

Wegovy vs other weight-loss approaches

Side effects affecting weight-loss outcomes

Long-term outlook — what happens after a year?

FAQ about Wegovy for weight loss

For weight loss for other GLP-1 medications